D-0117-2024 Class I Ongoing

Recalled by Exela Pharma Sciences LLC — Lenoir, NC

FDA drug recall D-0117-2024 was initiated by Exela Pharma Sciences LLC on Oct 18, 2023 and is designated Class I. Reason for recall: Presence of Particulate Matter: Silicone The recall status is ongoing. Affected quantity: 23,425 vials.

Recall Details

Product Type
Drugs
Report Date
Nov 29, 2023
Initiation Date
Oct 18, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
23,425 vials

Product Description

Midazolam in 0.8% Sodium Chloride Injection 100 mg/100 mL (1mg/mL), 100 mL Single-Dose Vial, 25 count carton, Ready to Use For Intravenous Infusion Only Preservative Free, Rx Only, Manufactured and Distributed by Exela Pharma Sciences, LLC, Lenoir, NC 28645, (Vial NDC 51754-2131-1; Carton NDC 51754-2131-4).

Reason for Recall

Presence of Particulate Matter: Silicone

Distribution Pattern

Nationwide

Code Information

Lot # 10001088 exp 07/31/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0117-2024
openFDA file date
Nov 3, 2026
Loaded by RegDataLab
Nov 4, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0117-2024. Report a data issue: hello@regdatalab.com.